

## References

- Adams, J. P., & Sweatt, J. D. (2002). Molecular psychology: Roles for the ERK MAPK cascade in memory. *Annual Review of Pharmacology and Toxicology*, *42*, 135–163.
- Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rhanama, N. P., Nathanson, N. M., et al. (2003). Selective cognitive dysfunction in acetylcholine M1 muscarinic mutant mice. *Nature Neuroscience*, *6*, 51–58.
- Apparsundaram, S., Martinez, V., Parikh, V., Kozak, R., & Sarter, M. (2005). Increased capacity and density of choline transporters situated in synaptic membranes of the right medial prefrontal cortex of attentional task-performing rats. *Journal of Neuroscience*, *25*, 3851–3856.
- Badio, B., & Daly, J. W. (1994). Epibatidine, a potent analgesic and nicotinic agonist. *Molecular Pharmacology*, *45*, 563–569.
- Bazalakova, M. H., & Blakely, R. D. (2006). The high-affinity choline transporter: A critical protein for sustaining cholinergic signaling as revealed in studies of genetically altered mice. *Handbook of Experimental Pharmacology*, *175*, 525–544.
- Bierut, L. J. (2010). Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. *Trends in Pharmacological Sciences*, *31*, 46–51.
- Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Gruzza, R. A., Xuei, X., et al. (2008). Variants in nicotinic receptors and risk for nicotine dependence. *The American Journal of Psychiatry*, *165*, 1163–1171.
- Birdsall, N. J. M., Burgen, A. S. V., & Hulme, E. C. (1978). The binding of agonists to brain muscarinic receptors. *Molecular Pharmacology*, *14*, 723–736.
- Bordia, T., Campos, C., Huang, L., & Quik, M. (2008). Continuous and intermittent nicotine

- treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. *Journal of Pharmacology and Experimental Therapeutics*, *327*, 239–247.
- Bowman, W. C. (2006). Neuromuscular block. *British Journal of Pharmacology*, *147*(Suppl. 1), S277–286.
- Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J., Smit, A. B., et al. (2001). Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature*, *411*, 269–276.
- Celie, P. H., van Rossum-Fikkert, S. E., van Dijk, W. J., Brejc, K., Smit, A. B., & Sixma, T. K. (2004). Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. *Neuron*, *41*, 907–914.
- Champtiaux, N., & Changeux, J. P. (2004). Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. *Acetylcholine in the Cerebral Cortex*, *145*, 235–251.
- Changeux, J. P. (2010). Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. *Nature Reviews Neuroscience*, *11*, 389–401.
- Changeux, J. P., Devillers-Thiéry, A., & Chemouilli, P. (1984). Acetylcholine receptor: An allosteric protein. *Science*, *225*, 1335–1345.
- Colquhoun, D., Ogden, D. C., & Mathie, A. (1987). Nicotinic acetylcholine receptors of nerve and muscle: Functional aspects. *Trends in Pharmacological Sciences*, *8*, 465–472.
- Conn, P. J., Jones, C. K., & Lindsley, C. W. (2009). Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. *Trends in Pharmacological Sciences*, *30*, 148–155.

- Cossins, J., Webster, R., Maxwell, S., Burke, G., Vincent, A., & Beeson, D. (2004). A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. *Human Molecular Genetics*, *13*, 2947–2957.
- Dale, H. H. (1914). The action of certain esters and ethers of choline, and their relation to muscarine. *Journal of Pharmacology and Experimental Therapeutics*, *6*, 147–190.
- Dale, H. H., & Dudley, H. W. (1929). The presence of histamine and acetylcholine in the spleen of the ox and the horse. *Journal of Physiology*, *68*, 97–123.
- Dale, H. H., Feldberg, W., & Vogt, Release of acetylcholine at voluntary motor nerve endings. *The Journal of Physiology (London)*, *86*, 353–380.
- Dajas-Bailador, F., & Wonnacott, S. (2004). Nicotinic acetylcholine receptors and the regulation of neuronal signalling. *Trends in Pharmacological Sciences*, *25*, 317–324.
- Duttaroy, A., Gomeza, J., Gan, J. W., Siddiqui, N., Basile, A. S., Harman, W. D., et al. (2002). Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. *Molecular Pharmacology*, *62*, 1084–1093.
- Ferguson, S. M., & Blakely, R. D. (2004). The choline transporter resurfaces: New roles for synaptic vesicles?. *Molecular Interventions*, *4*, 22–37.
- Fisher, S. K. (1986). Inositol lipids and signal transduction at CNS muscarinic receptors. *Trends in Pharmacological Sciences Supplement: Subtypes of Muscarinic Receptors II*, 61–65.
- Forster, G. L., Yeomans, J. S., Takeuchi, J., & Blaha, C. D. (2001). M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. *Journal of Neuroscience*, *21*(RC 190), 1–6.
- Govind, A. P., Vezina, P., & Green, W. N. (2009). Nicotine-induced upregulation of nicotinic receptors: Underlying mechanisms and relevance to nicotine

- addiction. *Biochemical Pharmacology*, 78, 756–765.
- Grønlien, J. H., Håkerud, M., Ween, H., Thorin-Hagene, K., Briggs, C. A., Gopalakrishnan, M., et al. (2007). Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. *Molecular Pharmacology*, 72, 715–724.
- Hasselmo, M. E., & Sarter, M. (2010). Modes and models of forebrain cholinergic neuromodulation of cognition. *Neuropsychopharmacology* (Epub ahead of print)
- Johnson, G., Swart, C., & Moore, S. W. (2008). Interaction of acetylcholinesterase with the G4 domain of the laminin alpha1-chain. *Biochemical Journal*, 411, 507–514.
- Karlin, A. (2002). Emerging structure of the nicotinic acetylcholine receptors. *Nature Reviews Neuroscience*, 3, 102–114.
- Kubo, T., Fukuda, K., Mikami, A., Maeda, A., Takahashi, H., Mishina, M., et al. (1986). Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. *Nature*, 323, 411–416.
- Kuryatov, A., Onksen, J., & Lindstrom, J. (2008). Roles of accessory subunits in alpha4beta2(\*) nicotinic receptors. *Molecular Pharmacology*, 74, 132–143.
- Langley, J. N. (1906). On nerve endings and on special excitable substances in cells. *Proceedings of the Royal Society of London. Series B*, 78, 170–194.
- Langmead, C. J., Watson, J., & Reavill, C. (2008). Muscarinic acetylcholine receptors as CNS drug targets. *Pharmacology & Therapeutics*, 117, 232–243.
- Le Novère, N., & Changeux, J. P. (1995). Molecular evolution of the nicotinic acetylcholine receptor: An example of multigene family in excitable cells. *Journal of Molecular Evolution*, 40, 155–172.
- Leonard, S., Mexal, S., & Freedman, R. (2007). Smoking, genetics and schizophrenia: Evidence

- for self medication. *Journal of Dual Diagnosis*, 3, 43–59.
- Liao, D. L., Hong, C. J., Chen, Y. E., Lee, S. M., & Chang, C. Y. (2003). Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. *Neuropsychobiology*, 48(2), 72–76.
- Lindstrom, J. (2002). Autoimmune diseases involving nicotinic receptors. *Journal of Neurobiology*, 53, 656–665.
- Loewi, O. (1921). Ueber humorale Uebertragbarkeit der herznervenwirkung. *Pfluegers Archiv General Physiology*, 189, 239–242.
- Liu, Z., Zhang, J., & Berg, D. K. (2007). Role of endogenous nicotinic signaling in guiding neuronal development. *Biochemical Pharmacology*, 74, 1112–1119.
- Livingstone, P. D., & Wonnacott, S. (2009). Nicotinic acetylcholine receptors and the ascending dopamine pathways. *Biochemical Pharmacology*, 78, 744–755.
- Maehle, A. H., Prüll, C. R., & Halliwell, R. F. (2002). The emergence of the drug receptor theory. *Nature Reviews Drug Discovery*, 1, 637–641.
- Massoulié, J., & Millard, C. B. (2009). Cholinesterases and the basal lamina at vertebrate neuromuscular junctions. *Current Opinion in Pharmacology*, 9, 316–325.
- Massoulié, J. (2002). The origin of the molecular diversity and functional anchoring of cholinesterases. *Neurosignals*, 11, 130–143.
- McIntosh, J. M., Absalom, N., Chebib, M., Elgoyhen, A. B., & Vincler, M. (2009). Alpha9 nicotinic acetylcholine receptors and the treatment of pain. *Biochemical Pharmacology*, 78, 693–702.
- Millar, N. S., & Gotti, C. (2009). Diversity of vertebrate nicotinic acetylcholine receptors. *Neuropharmacology*, 56, 237–246.

- Murrin, L. C., & Kuhar, M. J. (1976). Activation of high affinity choline uptake *in vitro* by depolarizing agents. *Molecular Pharmacology*, *12*, 1082–1090.
- Okuda, T., Haga, T., Kanai, Y., Endou, H., Ishihara, T., & Katsura, I. (2000). Identification and characterization of the high affinity choline transporter. *Nature Neuroscience*, *3*, 120–125.
- Paton, W. D., & Zaimis, E. J. (1949). The pharmacological actions of polymethylene bistrimethylammonium salts. *British Journal of Pharmacology*, *120*(Suppl. 1997), 60–79.
- Perrier, A. L., Massoulié, J., & Krejci, E. (2002). PRiMA: The membrane anchor of acetylcholinesterase in the brain. *Neuron*, *33*, 275–285.
- Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., et al. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. *Nature*, *391*, 173–177.
- Picciotto, M. R., Alreja, M., & Jentsch, D. (2002). Acetylcholine. In K. L. Davis, D. Charney, J. T. Coyle & C. Nemeroff (Eds.), *Neuropsychopharmacology: The fifth generation of progress* (pp. 1–14). Brentwood, TN: Amer. Coll. of Neuropsychopharmacology.
- Quik, M., O'Neill, M., & Perez, X. A. (2007). Nicotine neuroprotection against nigrostriatal damage: Importance of the animal model. *Trends in Pharmacological Sciences*, *28*, 229–235.
- Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. *Trends in Pharmacological Sciences*, *28*, 316–325.
- Seeger, T., Fedorova, I., Zheng, F., Miyakawa, T., Koustova, E., Gomeza, J., et al. (2004). M2 muscarinic acetylcholine knock-out mice show deficits in behavioral flexibility, working

- memory and hippocampal plasticity. *Journal of Neuroscience*, 24, 10117–10127.
- Silman, I., & Sussman, J. L. (2005). Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. *Current Opinion in Pharmacology*, 5, 293–302.
- Silman, I., & Sussman, J. L. (2008). Acetylcholinesterase: How is structure related to function?. *Chemico-Biological Interactions*, 175, 3–10.
- Sine, S. M., & Engel, A. G. (2006). Recent advances in Cys-loop receptor structure and function. *Nature*, 440, 448–455.
- Soreq, H., & Seidman, S. (2001). Acetylcholinesterase—new roles for an old actor. *Nature Reviews Neuroscience*, 2, 294–302.
- Steinlein, O. K., & Bertrand, D. (2008). Neuronal nicotinic acetylcholine receptors: From the genetic analysis to neurological diseases. *Biochemical Pharmacology*, 76, 1175–1183.
- Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., et al. (1991). Atomic structure of acetylcholinesterase from *Torpedo californica*: A prototypic acetylcholine-binding protein. *Science*, 253, 872–879.
- Sussman, J. L., & Silman, I. (1992). Acetylcholinesterase: Structure and use as a model for specific cation–protein interactions. *Current Opinion in Structural Biology*, 2, 721–729.
- Taylor, P., & Radic, Z. (1994). The cholinesterases: From genes to proteins. *Annual Review of Pharmacology and Toxicology*, 34, 281–320.
- Unwin, N. (2005). Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. *Journal of Molecular Biology*, 346, 967–989.
- Verderio, C., Rossetto, O., Grumelli, C., Frassoni, C., Montecucco, C., & Matteoli, M. (2006). Entering neurons: Botulinum toxins and synaptic vesicle recycling. *Embo Journal*, 7, 995–999.

- Vetter, D. E., Katz, E., Maison, S. F., Taranda, J., Turcan, S., Ballesterro, J., et al. (2007). The alpha10 nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system. *Proceedings of the National Academy of Sciences of the United States of America*, *104*, 20594–20599.
- Wess, J. (1996). Molecular biology of muscarinic acetylcholine receptors. *Crc Critical Reviews in Clinical Neurobiology*, *10*, 69–99.
- Wess, J., Eglen, R. M., & Gautam, D. (2007). Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development. *Nature Reviews Drug Discovery*, *6*, 721–733.
- Wessler, I., & Kirkpatrick, C. J. (2008). Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. *British Journal of Pharmacology*, *154*, 1558–1571.
- Xu, W., Gelber, S., Orr-Urtreger, A., Armstrong, D., Lewis, R. A., Ou, C. N., et al. (1999). Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. *Proceedings of the National Academy of Sciences of the United States of America*, *96*, 5746–5751.
- Xu, W., Orr-Urtreger, A., Nigro, F., Gelber, S., Sutcliffe, C. B., Armstrong, D., et al. (1999). Multiorgan autonomic dysfunction in mice lacking the beta2 and the beta4 subunits of neuronal nicotinic acetylcholine receptors. *Journal of Neuroscience*, *19*, 9298–9305.